Literature DB >> 1716207

Defective assembly of class I major histocompatibility complex molecules in an embryonic cell line.

E K Bikoff1, G R Otten, E J Robertson.   

Abstract

Developmentally regulated expression of the products of the major histocompatibility complex (MHC) is thought to play a key role in maternal tolerance of the fetal allograft. Here we analyze a cell line (EE2H3), derived from early post-implantation-stage mouse embryos, that is defective for MHC class I assembly. To follow expression of a single well-defined class I product, we introduced the H-2Dd gene under control of the human beta-actin promoter. We found that the transfected EE2H3 cells expressed abundant levels of H-2Dd heavy chains and beta 2-microglobulin protein, but only small amounts of H-2Dd surface protein. Surface expression was rescued by the addition of an appropriate antigenic peptide, or by culturing the cells at low temperature. The phenotype exhibited by EE2H3 is thus remarkably similar to that described for class I-negative somatic cell variants selected using antibodies and complement. However, a striking difference was that surface expression in H-2Dd-transfected EE2H3 cells was markedly enhanced in response to treatment with interferon. Thus, we have identified a novel class I assembly-defective cell line. Considering that EE2H3 was established from primary cultures of mouse embryo cells without immunoselection, and is therefore likely to represent a cell population normally present in post-implantation-stage embryos, these findings raise the possibility that expression of class I surface antigens during early development may in part be controlled post-translationally at the level of MHC class I assembly.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1716207     DOI: 10.1002/eji.1830210905

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  7 in total

1.  Developmental failure of chimeric embryos expressing high levels of H-2Dd transplantation antigens.

Authors:  L Jaffe; E J Robertson; E K Bikoff
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-01       Impact factor: 11.205

2.  Control of vaccinia virus skin lesions by long-term-maintained IFN-gamma+TNF-alpha+ effector/memory CD4+ lymphocytes in humans.

Authors:  Bénédicte Puissant-Lubrano; Philippe Bossi; Frederick Gay; Jean-Marc Crance; Olivia Bonduelle; Daniel Garin; François Bricaire; Brigitte Autran; Behazine Combadière
Journal:  J Clin Invest       Date:  2010-04-01       Impact factor: 14.808

3.  The natural killer cell receptor Ly-49A recognizes a peptide-induced conformational determinant on its major histocompatibility complex class I ligand.

Authors:  M Orihuela; D H Margulies; W M Yokoyama
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

4.  Analysis of the structure of empty and peptide-loaded major histocompatibility complex molecules at the cell surface.

Authors:  B Catipović; G Talluri; J Oh; T Wei; X M Su; T E Johansen; M Edidin; J P Schneck
Journal:  J Exp Med       Date:  1994-11-01       Impact factor: 14.307

5.  Different vaccine vectors delivering the same antigen elicit CD8+ T cell responses with distinct clonotype and epitope specificity.

Authors:  Mitsuo Honda; Rui Wang; Wing-Pui Kong; Masaru Kanekiyo; Wataru Akahata; Ling Xu; Kazuhiro Matsuo; Kannan Natarajan; Howard Robinson; Tedi E Asher; David A Price; Daniel C Douek; David H Margulies; Gary J Nabel
Journal:  J Immunol       Date:  2009-07-20       Impact factor: 5.422

6.  Comparison of cell lines deficient in antigen presentation reveals a functional role for TAP-1 alone in antigen processing.

Authors:  R Gabathuler; G Reid; G Kolaitis; J Driscoll; W A Jefferies
Journal:  J Exp Med       Date:  1994-10-01       Impact factor: 14.307

7.  Major histocompatibility complex conformational epitopes are peptide specific.

Authors:  B Catipović; J Dal Porto; M Mage; T E Johansen; J P Schneck
Journal:  J Exp Med       Date:  1992-12-01       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.